J Korean Orthop Assoc.  2003 Dec;38(7):741-747.

Efficacy of Cyclic Intravenous Pamidronate Therapy for Children with Osteogenesis Imperfecta

  • 1Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul, Korea.
  • 2Department of Orthopaedic Surgery, Seoul National University Children's Hospital, Seoul, Korea. tjcho@snu.ac.kr


We report the results of cyclic intravenous pamidronate therapy for children with osteogenesis imperfecta. MATERIALS AND METHODS: Fourteen patients with mean age 2.7 years were included in this study. Clinical evaluation included: fracture frequency, height gain, activity of daily living, and subjective changes. Bone mineral densitometry, simple radiographic findings, and the change in vertebral height were evaluated. Serum levels of calcium, osteocalcin and the urinary excretion of calcium and N-telopeptide of type I collagen (NTx) were monitored. Histologic study was performed on iliac crest apophysis biopsy samples. RESULTS: Fracture frequency significantly decreased, from a pre-treatment 0.99 per year per patient to 0.28 per year per patient duringtreatment. Height gain was not affected. Five patients reported subjective improvement. Bone mineral density increased in both lumbar spine and the femur neck. Urinary excretion of NTx and calcium were significantly reduced during each treatment cycle, but were restored at the following cycle. Eleven patients had transient asymptomatic hypocalcemia. A transient febrile reaction was observed in 8 patients during the first cycle, and 4 patients showed a mild increase in the serum transaminase level. CONCLUSIONS: Cyclic intravenous pamidronate treatment is safe and effective for children with osteogenesis imperfecta.


Osteogenesis imperfecta; Pamidronate
Full Text Links
  • JKOA
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr